Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
UPC US​

Universe Pharmaceuticals INC Class A(UPC US)

$4.34-0.040.91%Ext:$3.55-0.7918.20%(Market Closed · 23:55:17 UTC)

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees

Universe Pharmaceuticals INC Class A — Company Profile

Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Gang Lai
Headquarters
Ji'An, JX, CN
IPO Date
Mar 23, 2021
Employees
216
Website
www.universe-pharmacy.com

Key Metrics

Price
$4.50
Market Cap
$2.84M
Revenue (TTM)
$17.86M
Net Income (TTM)
$-3672055.00
EPS (TTM)
-1055.75
P/E (TTM)
0.00
P/B (TTM)
0.05
Dividend Yield
0.00%
ROE (TTM)
-6.54%
ROA (TTM)
-5.30%
Operating Margin
-16.33%
Beta
0.28

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.

Website
www.universe-pharmacy.com
Location
Ji'An, JX, CN
Phone86 571 8755 5823
Employees216
CEOGang Lai
Sector
Health Care
Industry
Pharmaceuticals
IPO DateMar 23, 2021

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

News

  • Law Offices of Howard G. Smith Announces Investigation of Universe Pharmaceuticals INC.12 Oct
  • The Law Offices of Frank R. Cruz Announces Investigation of Universe Pharmaceuticals INC.7 Oct
  • Universe Pharmaceuticals INC (NASDAQ:UPC) Stock Short Interest Rises 154.7%29 Sep

Key Stats

Trading

Px/Chg 1D$4.50 / +4.41%
Avg Volume281.89K
Beta0.28
Mkt Cap2.84M
FD Mkt Cap3.10M

Float

Shrs Out/Float631.76K / 487.25K
Short Float0.49%
Days to Cover1.00
Stock Repurchased$0.00

Current Valuation

EV-21492181.50
EV/EBITDA0.00
EV/Sales0.00
P/B0.05
P/S0.00
FCF Yield-273.78%
ROE-6.54%
ROA-5.30%
Current Ratio4.07

Estimates

P/E0.00
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgAug '22Aug '23Sep '24Jan '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-1.411.07-0.57-0.20-0.00-7.34
Price / Sales0.150.250.120.040.000.33
Price / Book Value0.080.210.110.030.000.05
Price / Free Cash Flow-0.71-0.78-3.511.13-0.00-0.37
ENTERPRISE VALUE METRICS
Enterprise Value-6.08.43.21.4-21.5-21.5
Enterprise Value / Sales-0.620.170.080.04-0.93-2.47
Enterprise Value / EBITDA119.220.59-0.49-0.442.92593.53
Enterprise Value / EBIT15.640.61-0.46-0.382.7475.68

Financials

Full Financials
Millions USD5Yr CAGR (%)Sep '21Sep '22Sep '23Sep '24Sep '25
INCOME STATEMENT
Revenue-21.9%48.040.132.323.017.9
Gross Income-29.4%25.321.910.36.16.3
EBITDA—14.2-6.4-3.2-7.4-2.9
EBIT—13.8-6.9-3.7-7.8-3.4
Net Income—11.3-8.7-6.2-8.7-3.7
EPS (Diluted)—2,147.18-1,475.02-1,040.53-1,436.12-1,055.75
BALANCE SHEET
Cash & ST Inv11.4%21.818.918.529.533.6
Total Assets-30.1%70.159.553.368.069.3
Total Liabilities4.1%11.213.113.822.513.2
Total Shareholder Equity-1.2%58.946.439.545.556.1
CASH FLOW
Net Operating Cash Flow25.2%-2.1-1.31.1-9.5-5.1
Cap Ex-60%-13.5-0.1-0.0-0.4-0.3
Free Cash Flow-23.3%-15.6-1.41.1-9.9-5.4

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)4.33
Basic Shares0.63
Market Cap2.7
Diluted Shares0.00
Fully Diluted Shares Outstanding0.00
Fully Diluted Market Cap0.0
+Consolidated Debt9.3
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-33.6
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value-21.6

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US